Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/21110
Title: Photobiomodulation for the management of radiation dermatitis: the DERMIS trial, a pilot study of MLS® laser therapy in breast cancer patients
Authors: Censabella, S.
Claes, S.
ROBIJNS, Jolien 
BULENS, Paul 
MEBIS, Jeroen 
Issue Date: 2016
Source: Supportive care in cancer, 24(9), p. 3925-3933
Abstract: PURPOSE: The aim of this study was to assess the effectiveness and acceptability of photobiomodulation using MLS® laser therapy (LT) in the management of acute radiation dermatitis (RD). METHODS: We compared two successive groups of breast cancer patients undergoing identical radiotherapy regimens post-lumpectomy. Both groups received our standard skin care but the second group received six additional LT sessions (beam area 19.635 cm2, 0.168 W/cm2, 4 J/cm2), starting at fraction 20 of radiotherapy (control and LT group, N = 41 and 38, respectively). The clinical outcomes were the severity of RD (using the Radiation Therapy Oncology Group [RTOG] criteria and the Radiotherapy-Induced Skin Reaction Assessment Scale [RISRAS]) and dermatology-specific quality of life (Skindex-16) before the start of LT and at the end of radiotherapy. Secondary outcomes were patients' ratings of skin care or LT (pleasantness, soothing effect, and global satisfaction). RESULTS: Skin toxicity was equivalent between the groups before the start of LT but significantly differed at the end of radiotherapy, with an aggravation in the control but not in the LT group (e.g., 29 versus 3 % of RTOG grade 2 RD, respectively, P < 0.005). We found no significant group differences with respect to quality of life. However, the RISRAS subjective score decreased in the LT group only, implying a decreased impact of RD on patients' quality of life. Finally, patients' ratings were significantly higher for LT than for standard care. CONCLUSIONS: These findings suggest that LT might be effective to manage acute RD and warrant further research. TRIAL REGISTRATION: Clinical trial number: NCT01932073. https://clinicaltrials.gov/ct2/show/NCT01932073 .
Notes: Censabella, S (reprint author), Jessa Hosp, Div Med Oncol, Campus Virga Jesse,Stadsomvaart 11, B-3500 Hasselt, Belgium. Sandrine.Censabella@jessazh.be
Keywords: breast neoplasms; low level laser therapy; photobiomodulation; radiation; radiation oncology; radiotherapy-induced skin reactions
Document URI: http://hdl.handle.net/1942/21110
ISSN: 0941-4355
e-ISSN: 1433-7339
DOI: 10.1007/s00520-016-3232-0
ISI #: 000380677200031
Rights: © Springer-Verlag Berlin Heidelberg 2016
Category: A1
Type: Journal Contribution
Validations: ecoom 2017
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
10.1007_s00520-016-3232-0.pdf
  Restricted Access
published version631.11 kBAdobe PDFView/Open    Request a copy
Show full item record

SCOPUSTM   
Citations

15
checked on Sep 2, 2020

WEB OF SCIENCETM
Citations

25
checked on May 21, 2022

Page view(s)

60
checked on May 25, 2022

Download(s)

40
checked on May 25, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.